Alpha Omega Cohort

  • Hoogeveen EK, Geleijnse JM, Giltay EJ, Soedamah-Muthu SS, de Goede J, Oude Griep LM, Stijnen T, Kromhout D. Kidney function and specific mortality in 60-80 years old post-myocardial infarction patients: A 10-year follow-up study. PLoS ONE 2017;12:e0171868.
  • Heeres RH, Hoogeveen EK, Geleijnse JM, de Goede J, Kromhout D, Giltay EJ. Kidney dysfunction, systemic inflammation and mental well-being in elderly post-myocardial infarction patients. BMC Psychol 2017;5:1-10.
  • Sijtsma FP, Soedamah-Muthu SS, de Goede J, Oude Griep LM, Geleijnse JM, Giltay EJ, de Boer MJ, Jacobs DR Jr, Kromhout D. Healthy eating and lower mortality risk in a large cohort of cardiac patients who received state-of-the-art drug treatment. Am J Clin Nutr 2015;105:1527-33.
  • Rius-Ottenheim N, Geleijnse JM, Kromhout D, van der Mast RC, Zitman FG, Giltay EJ. Physical activity after myocardial infarction: is it related to mental health? Eur J Prev Cardiol 2013;20:399-408.
  • Rius-Ottenheim N, Kromhout D, Craen AJM de, Geleijnse JM, Mast RC van der, Zitman FG, Westendorp RG, Slagboom PE, Giltay EJ. Parental longevity correlates with offspring’s optimism in two cohorts of community-dwelling older subjects. Age & Aging 2012;34:461–468.
  • Soedamah-Muthu SS, Geleijnse JM, Giltay EJ, Kromhout D. Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline data. BMJ open 2012;31:2-6.
  • Soedamah-Muthu SS, Geleijnse JM, Giltay EJ, Goede J de, Oude Griep LM, Waterham E, Teitsma-Jansen AM, Mulder BJM, Boer MJ de, Deckers JW, Zock PL, Kromhout D  for the  Alpha Omega Trial GroupLevels and trends in cardiovascular risk factors and drug treatment in 4837 elderly Dutch myocardial infarction patients between 2002 and 2006. Neth Heart J 2012;20:102–109.
  • Van de Rest O, de Goede J, Sytsma F, Oude Griep LM, Geleijnse JM, Kromhout D, Giltay EJ. Association of n-3 long-chain PUFA and fish intake with depressive symptoms and low dispositional optimism in older subjects with a history of myocardial infarction. Br J Nutr 2010;103:1381-1387.
  • De Jong HJI, de Goede J, Oude Griep LM, Geleijnse JM. Alcohol consumption and blood lipids in elderly coronary patients. Metabolism 2008;57:1286-1292.
  • Giltay EJ, Geleijnse JM, Schouten EG, Katan MB, Kromhout D. High stability of markers of cardiovascular risk in blood samples. Clin Chem 2003;49:652-655.

Alpha Omega Trial

Main publication:

n–3 fatty acids and cardiovascular events after myocardial infarction.

Kromhout D, Giltay EJ, Geleijnse JM for the Alpha Omega Trial Group. N Engl J Med 2010;363:2015-2026.

Supplementary appendix (PDF)

Kaplan-Meier curves and hazard ratios.

Main findings by n-3 fatty acid treatment group:

  • Hoogeveen EK, Geleijnse JM, Kromhout D, Van’t Sant P, Gemen EF, Kusters R, Giltay EJ. No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: The Alpha Omega Trial. Eur J Prev Cardiol 2014;22:648-55.
  • Hoogeveen EK, Geleijnse JM, Kromhout D, Stijnen T, Gemen EF, Kusters R, Giltay EJ. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clin J Am Soc Nephrol 2014;9:1676-83.
  • Hoogeveen EK, Geleijnse JM, Kromhout D, Giltay EJ. No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: The Alpha Omega Trial. Eur J Prev Cardiol 2014;21:1429-36.
  • Brouwer IA, Geleijnse JM, Klaasen VM, Smit LA, Giltay EJ, Goede J de, Heijboer AC, Kromhout D, Katan MB. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): Results from the Alpha Omega Trial. PLoS One 2013;8:e81519.
  • Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty acids on cognitive decline: A randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. Alzheimer´s Dementia 2012;8:278–287.
  • Giltay EJ, Geleijnse JM, Heijboer AC, Goede J de, Oude Griep LM, Blankenstein MA, Kromhout D. No effects of n-3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. Int J Androl 2012;35:680-7.
  • Eussen SRBM, Geleijnse JM, Giltay EJ, Rompelberg CJM, Klungel OH, Kromhout D. Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. Eur Heart J 2012;33:1582–1588.
  • Kromhout D, Boer M-J de. Response to comment on: Kromhout et al. n-3 Fatty acids, ventricular arrhythmia-related events and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care 2012;6:E46.
  • Kromhout D, Geleijnse JM, de Goede J, Oude Griep LM, Mulder BJM, de Boer M-J, Deckers JW, Boersma E, Zock PL, Giltay EJ. N-3 fatty acids, ventricular arrhythmia related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care 2011;34:2515-2520.
  • Giltay EJ, Geleijnse JM, Kromhout D. Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. Am J Clin Nutr 2011;94:1442–1450.
  • Kromhout D, Giltay EJ, Geleijnse JM. N-3 Fatty acids and cardiovascular events. Reply to letters to the editor. N Engl J Med 2011;364:880-881.
  • Geleijnse JM, Giltay EJ, Schouten EG, de Goede J, Oude Griep LM, Teitsma-Jansen AM, Katan MB, Kromhout D for the Alpha Omega Trial Group. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am Heart J 2010;159:539-546.